Relation between recurrence and expression of proliferating cell nuclear antigen, sialyl Lewis X, and sialyl Lewis a in lung cancer Jun-ichi Ogawa, MD, Akemi Sano, Sirosaku Koide, MD, Akira Shohtsu, MD The Journal of Thoracic and Cardiovascular Surgery Volume 108, Issue 2, Pages 329-336 (August 1994) DOI: 10.5555/uri:pii:S002252239470015X Copyright © 1994 Mosby, Inc. Terms and Conditions
Fig. 1 Disease-free survival according to blood vessel invasion (BVI), expression of sialyl LewisX (SLX), and proliferating cell nuclear antigen (PCNA) in adenocarcinomas. (p < 0.03: BVI (+) SLX (-, +) PCNA (+) versus BVI (+) SLX (++) PCNA (++). Fig. 1. Cont'd. Disease-free survival according to blood vessel invasion (BVI), sialyl Lewisa (CA19-9), and proliferating cell nuclear antigen (PCNA) in non-adenocarcinomas. p < 0.05: BVI(+) CA19-9 (–, +) PCNA (+) versus BVI (+) CA19-9 (++) PCNA (++). The Journal of Thoracic and Cardiovascular Surgery 1994 108, 329-336DOI: (10.5555/uri:pii:S002252239470015X) Copyright © 1994 Mosby, Inc. Terms and Conditions
Fig. 1 Disease-free survival according to blood vessel invasion (BVI), expression of sialyl LewisX (SLX), and proliferating cell nuclear antigen (PCNA) in adenocarcinomas. (p < 0.03: BVI (+) SLX (-, +) PCNA (+) versus BVI (+) SLX (++) PCNA (++). Fig. 1. Cont'd. Disease-free survival according to blood vessel invasion (BVI), sialyl Lewisa (CA19-9), and proliferating cell nuclear antigen (PCNA) in non-adenocarcinomas. p < 0.05: BVI(+) CA19-9 (–, +) PCNA (+) versus BVI (+) CA19-9 (++) PCNA (++). The Journal of Thoracic and Cardiovascular Surgery 1994 108, 329-336DOI: (10.5555/uri:pii:S002252239470015X) Copyright © 1994 Mosby, Inc. Terms and Conditions
Fig. 2 Disease-free survival in patients with recurrent tumors according to expression of proliferating cell nuclear antigen (PCNA) in adenocarcinomas. p < 0.01: PCNA (+) versus PCNA (++). Fig. 2. Cont'd Disease-free survival in the patients with recurrent tumors according to expression of proliferating cell nuclear antigen (PCNA) in nonadenocarcinomas. p < 0.01: PCNA (+) versus PCNA (++). The Journal of Thoracic and Cardiovascular Surgery 1994 108, 329-336DOI: (10.5555/uri:pii:S002252239470015X) Copyright © 1994 Mosby, Inc. Terms and Conditions
Fig. 2 Disease-free survival in patients with recurrent tumors according to expression of proliferating cell nuclear antigen (PCNA) in adenocarcinomas. p < 0.01: PCNA (+) versus PCNA (++). Fig. 2. Cont'd Disease-free survival in the patients with recurrent tumors according to expression of proliferating cell nuclear antigen (PCNA) in nonadenocarcinomas. p < 0.01: PCNA (+) versus PCNA (++). The Journal of Thoracic and Cardiovascular Surgery 1994 108, 329-336DOI: (10.5555/uri:pii:S002252239470015X) Copyright © 1994 Mosby, Inc. Terms and Conditions